Novartis AG researches, develops, manufactures, and markets healthcare products. The company operates through two segments, Innovative Medicines and Sandoz. Sandoz provides finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals.
Market Cap | 231.214 Billion | Shares Outstanding | 2.366 Billion | Avg 30-day Volume | 1.596 Million |
P/E Ratio | 23.4918 | Dividend Yield | 3.6878 | EPS | 3.19 |
Price to Revenue | 3.8003 | Debt to Equity | 0.0303 | EBITDA | 10.747 Billion |
Price to Book Value | 3.3504 | Operating Margin | 20.3455 | Enterprise Value | 172.123 Billion |
Current Ratio | 0.898 | EPS Growth | -0.304 | Quick Ratio | 0.541 |
1 Yr BETA | 0.3333 | 52-week High/Low | 105.61 / 79.64 | Profit Margin | 16.175 |
Operating Cash Flow Growth | -59.0165 | Free Cash Flow to Firm (FCFF) TTM | 8.269 Billion | Free Cash Flow to Equity (FCFE) TTM | 17.22 Billion |
Altman Z-Score | 2.2362 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-28 13:45:04 UTC | 4.9119 | 0.4081 | 1300000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-28 13:15:03 UTC | 4.9119 | 0.4081 | 1300000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-28 12:45:04 UTC | 4.9119 | 0.4081 | 1300000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 22:15:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 21:45:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 21:15:03 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 20:45:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 20:15:05 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 19:45:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 19:15:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 18:45:05 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 18:15:03 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 17:45:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 17:15:03 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 16:45:04 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 16:15:03 UTC | 4.9119 | 0.4081 | 2700000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 15:45:04 UTC | 4.9119 | 0.4081 | 1400000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 15:15:03 UTC | 4.9119 | 0.4081 | 1400000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 14:45:03 UTC | 5.0683 | 0.2517 | 1400000 |
NOVARTIS AG-SPONSORED ADR NVS | 2023-11-27 14:15:04 UTC | 5.0683 | 0.2517 | 1400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|
Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
---|---|---|---|---|---|---|---|---|---|---|
senator Sheldon Whitehouse | democrat | Senate | Filing | 2023-10-17 | 2023-09-20 | P | $15,001-$50,000 | |||
Hon. Daniel Goldman | House | Filing | 2023-08-04 | 2023-07-10 | S | $50,001-$100,000 |